When they did the Organon transaction, they had less left in the till than they do now.
The Greer IP is not the kind of licensing anyone was referring to or complaining about--and was not what they meant either, at the time. Spending next to nothing to expand Ampakine usage is not an issue--acquiring a non-Ampakine technology to develop in the clinic, that was the subject of dispute. Fortunately (at least in my opinion), they were able to change course.
NeuroInvestment
News 
Market Data 
Discover 
AI
